Vaccination Guide for
Immunosuppressed Patients with IBD

Treatment Options Overview

Edit Content

SHOULD TITRES BE CHECKED?

Considered immune if 2 documented doses of vaccine or positive serology­

BEFORE INITIATION OF IMMUNE SUPPRESSION

Contraindicated if plan to start therapy in < 4 weeks. Contraindicated in pregnancy.
When rapid protection is required, a minimum interval of 4 weeks between the 2 doses is acceptable.

WHAT TO DO IF ALREADY IMMUNOSUPPRESSED
(ON ANTI-TNF OR IMMUNOMODULATOR)

Contraindicated.

           
Edit Content

VACCINE

SHOULD TITRES BE CHECKED?

Considered immune if the following:

  • History of varicella of herpes zoster diagnosed by health care provider
  • Received 2 doses of varicella-containing vaccine
  • Born before 1970

Serology testing can be considered if patients do not meet above criteria.

BEFORE INITIATION OF IMMUNE SUPPRESSION

Contraindicated if plan to start therapy in < 4 weeks. Contraindicated in pregnancy.
When rapid protection is required, a minimum interval of 4 weeks between the 2 doses is acceptable.

WHAT TO DO IF ALREADY IMMUNOSUPPRESSED
(ON ANTI-TNF OR IMMUNOMODULATOR)

Contraindicated.

           
Edit Content

BRAND NAME / COMPANY / REIMBURSEMENT AND LOGISTICS PROGRAM (ORIGINAL MARKET DATE)

Stelara®/Janssen/BioAdvance® (2009)

CLASS

Monoclonal antibody interleukin (IL)-12/23 inhibitor

ACTION

Targets an overactive immune system by blocking two receptors called IL-12 and IL-23. By blocking these receptors, cells are slowed down, which reduces inflammation.

           
Edit Content

BRAND NAME / COMPANY / REIMBURSEMENT AND LOGISTICS PROGRAM (ORIGINAL MARKET DATE)

Entyvio®/Takeda/OnePath® (2015)

CLASS

Monoclonal antibody integrin receptor blocker

ACTION

Blocks integrin α4β7 protein that is found on the surface of white blood cells, thereby reducing intestinal inflammation. Inflammation elsewhere in the body is unaffected.
           
Edit Content

BRAND NAME / COMPANY / REIMBURSEMENT AND LOGISTICS PROGRAM (ORIGINAL MARKET DATE)

Skyrizi®/AbbVie/AbbVie Care (2019)

 

CLASS

Monoclonal antibody interleukin (IL)-23 inhibitor

ACTION

Targets IL-23 protein receptor, which is one of the proteins responsible for inflammation. Blocking this receptor contributes to reducing inflammation.

           
Edit Content

BRAND NAME / COMPANY / REIMBURSEMENT AND LOGISTICS PROGRAM (ORIGINAL MARKET DATE)

Rinvoq/Abbvie/Abbvie Care (2023)

 

CLASS

JAK Inhibitor

ACTION

JAKs are intracellular enzymes that activate the body’s immune response causing inflammation. JAK inhibitors block this pathway. Works by attaching to the JAK enzyme to lower its activity and to decrease inflammation in the body.